Dramatic changes in the marketplace have greatly increased the need for health economics and data mining in all phases of
development—especially for targeted therapies. The value proposition for such treatments needs to be carefully developed and
presented to payers. Payers may be willing to pay premium prices for targeted therapies, but only if they are demonstrably
safer or more effective than existing therapies.
William H. Crown is the president of i3 Innovus. He can be reached at email@example.com